BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $84 from $87 and keeps a Buy rating on the shares. While Q1 ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of SpringWorks Therapeutics Inc (Symbol: SWTX) entered into oversold territory, hitting an RSI ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Merck & Co. Inc. (MRK): Revenue from ... Jefferies singled out Structure Therapeutics Inc. (GPCR), Insmed Inc. (INSM) and SpringWorks Therapeutics Inc. (SWTX) Another biotech stock worth watching ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Similarly, the FDA in February signed off on SpringWorks’ rare disease drug Gomekli, which can now be used for adults and children with neurofibromatosis type 1 with symptomatic plexiform ...

Investing.com – Germany equities were higher at the close on Monday, as gains in the DAX Telecom, DAX Food & Beverage and DAX ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00. The company has a fifty day moving average price of $47.22 and a 200 day moving average price of $39.58.